证券日报网讯 12月2日，一品红在互动平台回答投资者提问时表示，截至2025年11月30日，公司股东总 户数20363户。 （文章来源：证券日报） ...

12月1日，一品红跌5.13%，截至发稿，报48.08元/股，成交2.71亿元，换手率1.32%，总市值217.17亿 元。一品红股价已经连续3天下跌，区间累计跌幅5.73%。 从基金十大重仓股角度 数据显示，博时基金旗下1只基金重仓一品红。博时新策略混合A（001522）三季度持有股数1.76万股， 占基金净值比例为1.85%，位居第七大重仓股。根据测算，今日浮亏损失约4.58万元。连续3天下跌期间 浮亏损失5.42万元。 博时新策略混合A（001522）成立日期2015年11月23日，最新规模5594.69万。今年以来收益7.34%，同 类排名6156/8199；近一年收益7.22%，同类排名6341/8131；成立以来收益50.29%。 博时新策略混合A（001522）基金经理为李重阳、罗霄。 截至发稿，李重阳累计任职时间2年299天，现任基金资产总规模11.06亿元，任职期间最佳基金回报 14.35%， 任职期间最差基金回报-19.59%。 罗霄累计任职时间3年64天，现任基金资产总规模187.79亿元，任职期间最佳基金回报26.8%， 任职期 间最差基金回报-0.96%。 风险提示：市场有风险，投资 ...

Core Insights - The company Yipinhong (300723) has received approval for three new drugs from the National Medical Products Administration, enhancing its product pipeline in the pediatric and chronic disease medication sectors [1][2] Drug Approvals - The three approved drugs include: - Esomeprazole magnesium enteric-coated suspension, indicated for gastroesophageal reflux disease and H. pylori eradication, with a projected sales scale of approximately 2.243 billion yuan in 2024 [1] - Ketoconazole sustained-release tablets, aimed at peripheral vascular diseases, with an expected sales scale of around 1.426 billion yuan in 2024 [1] - Compound polyethylene glycol (3350) electrolyte powder, for treating chronic constipation in children, with a projected sales scale of about 1.108 billion yuan in 2024 [2] Market Positioning - The approval of these drugs signifies the company's qualification to market these products domestically, thereby enriching its offerings in the pediatric and chronic disease medication fields and enhancing its competitive edge [2] Recent Developments - A week prior, the company announced the approval of a drug for treating mild to moderate Alzheimer's symptoms, with an expected sales scale of approximately 100 million yuan in 2024 [2] - The company is also advancing its innovative gout drug, AR882, which has completed the target enrollment of 680 patients in its domestic Phase III clinical trial [2][3] Clinical Trial Results - Data from completed global Phase II trials for AR882 indicate effective reduction of serum uric acid (sUA) and high rates of complete dissolution of gout stones in patients, providing a promising oral treatment option for chronic gout patients [3]

Market Performance - The pharmaceutical sector experienced a slight increase of +0.14% on November 28, 2025, underperforming the CSI 300 index by 0.11 percentage points, ranking 27th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (+1.53%), hospitals (+0.95%), and other biological products (+0.70%) performed well, while offline pharmacies (-0.55%), vaccines (-0.46%), and medical research outsourcing (-0.33%) lagged behind [1] - Top three gainers in individual stocks were Haiwang Pharmaceutical (+10.03%), Baihua Pharmaceutical (+10.01%), and Hefei China (+7.49%); the top three decliners were Yue Wannianqing (-13.71%), Zhongsheng Pharmaceutical (-10.00%), and Guangji Pharmaceutical (-9.98%) [1] Industry News - The CDE announced that AbbVie's Upadacitinib extended-release tablets are proposed for priority review, targeting severe alopecia areata in adults and adolescents aged 12 and above [2] - Upadacitinib is a JAK inhibitor effective for various immune-mediated inflammatory diseases, with a stronger inhibitory effect on JAK1 compared to JAK2, JAK3, and TYK2; this priority review in China suggests accelerated access for alopecia patients [2] Company News - Guobang Pharmaceutical (605507) announced an employee stock ownership plan involving 270 employees, aiming to raise up to 185 million yuan, with a stock cap of 10% of total equity and a duration of 24 months, including a 12-month lock-up period [3] - Tianen Kang (301263) reported that its subsidiary Shandong Huabo Kaisheng received a drug registration certificate for Baricitinib tablets from the National Medical Products Administration, confirming compliance with registration requirements [3] - Yipinhong (300723) announced that its subsidiary Guangzhou Yipinhong received approval for Esomeprazole Magnesium Enteric-Coated Suspension from the National Medical Products Administration, meeting registration standards [3] - Enhua Pharmaceutical (002262) stated that it received a drug registration certificate for Oxycodone Hydrochloride Extended-Release Tablets from the National Medical Products Administration, confirming compliance with registration requirements [3]

Group 1 - The core point of the article is that Yipinhong announced the approval of a drug registration certificate for its subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., regarding the sustained-release tablet of theobromine [2] Group 2 - The approval was granted by the National Medical Products Administration [2] - The announcement was made on the evening of November 28 [2]

Core Points - The company Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the drug registration certificate for Esomeprazole Magnesium Enteric-coated Suspension from the National Medical Products Administration [2] Company Summary - Yipinhong's subsidiary has successfully obtained regulatory approval for a new drug, which may enhance its product portfolio and market presence [2] - The approval of Esomeprazole Magnesium Enteric-coated Suspension indicates the company's commitment to expanding its offerings in the pharmaceutical sector [2] Industry Summary - The approval from the National Medical Products Administration reflects the regulatory environment's support for new drug development in the pharmaceutical industry [2] - This development may signal potential growth opportunities within the gastrointestinal treatment market, as Esomeprazole is commonly used for acid-related disorders [2]

Group 1 - The core point of the article is that Yipinhong has received a drug registration certificate from the National Medical Products Administration for its product, Compound Polyethylene Glycol (3350) Electrolyte Powder [2] Group 2 - The approval was granted to Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd. [2]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. to market Ketone Cocoa Alkaloid Sustained-Release Tablets, which are indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1: Product Approval - The approval includes a drug registration certificate for Ketone Cocoa Alkaloid Sustained-Release Tablets [1] - The tablets are designed to improve blood rheological properties by reducing blood viscosity, thereby enhancing blood flow in patients with chronic peripheral artery disease [1] Group 2: Mechanism of Action - Ketone Cocoa Alkaloid and its metabolites improve blood rheological characteristics in a dose-dependent manner [1] - The exact mechanism of action remains unclear, but it is known to enhance red blood cell deformability and improve leukocyte deformability while inhibiting neutrophil adhesion and activation [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of its drug, Ketoconazole Sustained-Release Tablets, which is indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Ketoconazole Sustained-Release Tablets [1] - The approved indication for the drug includes treatment for peripheral vascular diseases [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. to market Ketone Cocoa Alkaloid Sustained-Release Tablets, which are indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1: Product Approval - The approval includes a drug registration certificate for Ketone Cocoa Alkaloid Sustained-Release Tablets [1] - The tablets are designed to improve blood rheological properties by reducing blood viscosity, thereby enhancing blood flow in patients with chronic peripheral artery disease [1] Group 2: Mechanism of Action - Ketone Cocoa Alkaloid and its metabolites improve blood rheology in a dose-dependent manner, lowering blood viscosity and enhancing red blood cell deformability [1] - The exact mechanism of action for Ketone Cocoa Alkaloid remains unclear, but it is known to enhance the deformability of white blood cells and inhibit the adhesion and activation of neutrophils [1]